Show simple item record

dc.contributor.authorHamadani, M
dc.contributor.authorCollins, P
dc.contributor.authorSamaniego, F
dc.contributor.authorSpira, I
dc.contributor.authorDavies, A
dc.contributor.authorRadford, John A
dc.contributor.authorCaimi, P
dc.contributor.authorMenne,T
dc.contributor.authorBoni, J
dc.contributor.authorCruz, H
dc.contributor.authorFeingold, J
dc.contributor.authorHe, S
dc.contributor.authorWuerthner, J
dc.contributor.authorHorwitz, M
dc.date.accessioned2019-03-29T14:22:30Z
dc.date.available2019-03-29T14:22:30Z
dc.date.issued2018en
dc.identifier.citationHamadani M, Collins G, Samaniego F, Spira A, Davies A, Radford J, et al.Phase 1 study of Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma. Blood. 2018;132.en
dc.identifier.doi10.1182/blood-2018-99-118198en
dc.identifier.urihttp://hdl.handle.net/10541/621662
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1182/blood-2018-99-118198en
dc.titlePhase 1 study of Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphomaen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMemorial Sloan Kettering Cancer Center, Basking Ridge, NJen
dc.identifier.journalBlooden
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record